Clinical effects of online dialysate and infusion fluids

Hemodialysis International

Volumn 10, Issue SUPPL. 1, 2006, Pages

  Tetta, Ciro ^a,e   David, Salvatore ^b   Marcelli, Daniele ^a   Cogliati, Paolo ^a   Formica, Marco ^c   Inguaggiato, Paola ^c   Panichi, Vincenzo ^d  

^a FRESENIUS MEDICAL CARE   (Germany)

^b UNIVERSITY OF PARMA   (Italy)

^c S Croce and Carle General Hospital   (Italy)

^d UNIVERSITY OF PISA   (Italy)

^e NONE   (Germany)

Author keywords

Biocompatibility; Convection; Cytokines

Indexed keywords

BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; ENDOTOXIN; ERYTHROPOIETIN; INTERLEUKIN 1; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

AMYLOIDOSIS; ANEMIA; ATHEROSCLEROSIS; BACTERIUM CONTAMINATION; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHRONIC KIDNEY DISEASE; COMORBIDITY; CYTOKINE PRODUCTION; DIALYSATE; HEART MUSCLE ISCHEMIA; HEMODIAFILTRATION; HUMAN; HYPOTENSION; INFLAMMATION; MALNUTRITION; MEMBRANE PERMEABILITY; MORBIDITY; MORTALITY; NECROSIS; PREDICTION; PREVALENCE; PROTEIN BLOOD LEVEL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; SYMPTOMATOLOGY; TREATMENT OUTCOME; WATER CONTAMINATION; WATER QUALITY;

BACTERIA; HEMODIAFILTRATION; HEMODIALYSIS SOLUTIONS; HUMANS; INFLAMMATION; MORBIDITY; ONLINE SYSTEMS; SURVIVAL RATE;

EID: 33244462007     PISSN: 14927535     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2006.01194.x     Document Type: Review

References (61)

1. Lonnemann G, Behme TC, Lenzner B, et al. Permeabilità of dialyzer membranes to TNF alpha inducing substances derived from water bacteria. Kidney Int. 1992; 42: 61-68.
2. Leypoldt JK, Schmidt B, Gulrand HJ. Measurement of backfiltration rates during hemodialysis with highly permeable membranes. Blood Purif. 1991; 9:74-84.
3. Ronco C, Brendolan A, Ferini M, et al. A new scintigraphic method to characterize ultrafiltration in hollow fiber dialysers. Kidney Int. 1992; 41:1383-1393.
4. Association for the Advancement of Medical Instrumentation. Water treatment equipment for hemodialysis applications ANSI/AAMI RD62:2001 (document DS-1RD52, update 2004, http://www.aami.org/standards/downloadables/aamirevf.pdf).
5. AAMI: Dialysate for Hemodialysis (Committee Draft for Vote). AAMI/CDV-3 RD52:2004 Arlington, VA, U.S.A. 2004.
6. European Pharmacopoeia. Haemofiltration and for Haemodiafiltration, Solutions For, Vol. 1/2002:0861, 4th ed. Strasbourg: European Pharmacopoeia; 2003, 1283pp.
7. The EBPG Expert Group on Haemodialysis: Kessler M, Canaud M, Pedrini LA, Tattersall J, Marten ter Wee P, Vanholder R, Wanner C. European Best Practice Guidelines for Haemodialysis (part 1). Section IV. Nephrol Dial Transplant. 2002; 17(Suppl 7):45-62.
8. Sezione Piemonte e Valle d'Aosta della SIN (Italian Society of Nephrology). Linee guida per il controllo delle acque per emodialisi. Giorn It Nefrol. 2002; 19:104-107.
9. Direction générale de la santé. Direction des hôpitaux. Agence française de sécurité sanitaire des produits de santé. Circulaire DGS/DH/AFSSAPS No 2000/311 relative aux spécifications techniques et à la sécurité sanitaire de la pratique de l'hémofiltration et de l'hémodiafiltration en ligne dans les établissements de santé
10. Guías de Gestión de Calidal del líquido de di álisi (LD). Sociedad Española de Nefrologia. http://www.senefro.org/modules/subsection/files/agua.pdf.
11. Ramirez R, Carracedo J, Berdud I, et al. Microinflammation in hemodialysis is related to a preactivated subset of monocytes. Hemodialysis Int. 2006; 10(Suppl 1):S24-S27.
12. Schindler R. Inflammation and dialysate quality. Hemodialysis Int. 2006; 10(Suppl 1):S56-S59.
13. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002; 3:187-197.
14. US Renal Data System. Excerpts from the USRDS 1997 annual data report. Am J Kidney Dis. 1997; 30:S1-S195.
15. Parfey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol. 1999; 10:1606-1615.
16. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal failure. Am J Kidney Dis. 1998; 32(Suppl 5):S112-S119.
17. Ross R. Atherosclerosis: An inflammatory disease. N Engl J Med. 1999; 340:115-126.
18. Vasan RS, Sullivan LM, Roubenoff R, et al. Inflammatory markers and risk of heart failure in erderly subjects without prior myocardial infarction: The Framingham Heart Study. Circulation. 2003; 107:1486-1491.
19. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin and the risk of cardiovascular disease in apparently healty men. N Engl J Med. 1997; 336: 973-979.
20. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. New Engl J Med. 1994; 331:417-424.
21. Lagrand WK, Visser CA, Hermens WT, et al. C-reactive protein as a cardiovascular risk: More than an epiphenomenon? Circulation. 1999; 100:96-102.
22. Bhatt DL, Topol EJ. Need to test the arterial Inflammation hypothesis. Circulation. 2002; 106:136-140.
23. Stenvinkel P. Malnutrition and chronic inflammation as risk factors for cardiovascular disease in chronic renal failure. Blood Purif. 2001; 19:143-151.
24. Kaysen GA. Role of inflammation and its treatment in ESRD patients. Blood Purif. 2002; 20:70-80.
25. Lonnemann G. When good water goes bad: How it happens, clinical consequences and possibile solutions. Blood Purif. 2004; 22:124-129.
26. Panichi V, Migliori M, De Pietro S, et al. The link of biocompatiility to cytokine production. Kidney Int. 2000; 59(Suppl 76):96-103.
27. Schindler R, Beck W, Deppisch R, et al. Short bacterial DANN fragments: Detection in dialysate and induction of cytokines. J Am Soc Nephrol. 2004; 15:3207-3214.
28. Panichi V, De Pietro S, Andreine B, et al. Cytokine production in hemodiafiltration: A multicentre study Nephrol Dial Transplant. 1998; 13:1452-1459.
29. Panichi V, Tetta C, Rindi P, Palla R, Lonnemann G. Plasma C-reactive protein is linked to ackfiltration associated interleukin 6 production. ASAIO J. 1998; 744: M415-M417.
30. Canard B, Bosc JY, Leray H, et al. On line hemodiafiltration: State of the art. Nephrol Dial Transplant. 1998; 5:3-11.
31. Pizzarelli F, Cerrai T, Dattolo P, Tetta C, Maggiore Q. Convective treatments with on line production of replacement fluid: A clinical experience lasting 6 years. Nephrol Dial Transplant. 1998; 13:363-369.
32. Canaud B, Wizemann V, Pizzarelli F, et al. Cellular interleukin-1 receptor antagonist production in patients receiving on-line haemodiafiltration therapy. Nephrol Dial Transplant. 2001; 16:2181-2187.
33. Vaslaki L, Karatzon A, Voros P, et al. Can sterile and pyrogen-free on-line substitutio fluid be rotuineley delivered? A multicentre study on the microbiological safety of on-line hemodiafiltration. Nephrol Dial Transplant. 2000; 15(Suppl 1):74-78.
34. www.anaes.fr (Accessed April 10, 2005)
35. Cappelli G, Riccardi M, Perrone S, Bondi M, Ligabue G, Albertazzi A. Water treatment and monitor disinfection. Hemodialysis Int. 2006; 10(Suppl 1):S13-S18.
36. Canaud B, Bragg-Gresham JL, Marshall MR, et al. Patients receiving hemodiafiltration of haemofiltration have lower mortality risk than patients receiving hemodialysis without replacement fluid (HD) in Europe: The Dialysis Outcomes and Practice Patterns Study (DOPPS). J Amer Soc Nephrol. 2003; 14:SA-PC 140.
37. Jirka T, Cesare S, Di Benedetto T, Perera Chang M, Ponce P, Richards N. The impact of on-line hemodiafiltration on patient survival: Results from a large network database. Nephrol Dial Transpl. 2005; 20(Suppl 5):S044.
38. Mion M, Kerr PG, Argiles A, Canaud B, Flavier JL, Mion CM. Haemodiafiltration in high-cardiovascular-risk patients. Nephrol Dial Transplant. 1992; 7:453-454.
39. Donauer J, Scweiger C, Rumberger B, Krumme B, Boehler J. Reduction of hypotensive side effects during online-haemodiafiltration and low temperature haemodialysis. Nephrol Dial Transplant. 2003; 18:1616-1622.
40. Lonnemann G, Koch KM. Efficacy of ultrapure dialysate in the therapy and prevention of haemodialysis-associated amyoloidosis. Nephrol Dial Transplant. 2001; 16(Suppl 4):17-22.
41. Reznikov LL, Waksman J, Azam T, et al. Effect of advanced glycation end products on endotoxin-induced TNF-alfa, IL-1beta and Il.8 in human peripheral blood mononuclear cells. Clin Nephrol. 2004; 61: 324-336.
42. Ward A, Schmidt B, Hullin J, Hillebrand GF, Samtleben W. A comparison of on.line hemodiafiltration and high-flux hemodialysis: A prospective clinical study. J Am Soc Nephrol. 2000; 11:2344-2350.
43. Locatelli F, Marcelli D, Conte F, Limido A, Malberti F, Spott D. Comparison of mortality in ESRD patients on convective and diffusive extracorporeal treatments. Kidney Int. 1999; 55:286-293.
44. Schiffl H, Lang SM, Stratakis D, Fischer R. Effects of ultrapure dialysis fluid on nutritional status and inflammatory parameters. Nephrol Dial Transplant. 2001; 16: 1863-1869.
45. Hsu P-Y, Lin C-L, Yu C-C, et al. Ultrapure dialysate improves iron utilization and erythropoietin response in chronic hemodialysis patients - A prospective cross-over study. J Nephrol. 2004; 17:693-700.
46. Sitter T, Bergner A, Schiffl H. Dialysate related cytokine induction and response to recombinant human erythropoietin in hemodialysis patients. Nephrol Dial Transplant. 2000; 15:1207-1211.
47. Barany P, Divino Filho JC, Bergstrom J. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis. 1997; 29:565-568.
48. Maduell F, del Pozo C, Garcia H, et al. Change from conventional hemodiafiltration to on-line hemodiafiltration. Nephrol Dial Transplant. 1999; 14:1202-1207.
49. Lin C-L, Huang C-C, Yang C-W. Improved iron utilization and reduced erythropoietin resistance by on line hemodiafiltration. Blood Purif. 2002; 20:349-356.
50. Bonforte G, Grillo P, Zerbi S, Surian M. Improvement of anemia in hemodialysis patients treated by haemofiltration with high-volume online prepared substitution fluid. Blood Purif. 2002; 20:357-363.
51. Drueke T, Liberherr M, Cournot G. Pathophysiology of aluminium-induced bone disease. Contrib Nephrol. 1988; 64:109-112.
52. Berend K, van der Voet G, Boer WH. Acute Al encephalopathy in a dialysis center caused by a cement mortar water distribution pipe. Kidney Int. 2001; 59:746.
53. Jochimsen EM, Wayne W, Carnichael WW, et al. Liver failure and death after exposure to microsystins at a hemodialysis center in Brazil. N Engl J Med. 1998; 338: 873-878.
54. Bonnie-Schorn E, Grassmann A, Uhlenbusch-Koerwer I, Weber C, Vienken J. Water Quality in Hemodialysis. Berlin: PABST; 1998.
55. Ward DM. Chloramine removal from water used in hemodialysis. Adv Renal Replacement Ther. 1996; 3:337-347.
56. Cappelli G, Lusvarghi E. La qualità delle acque per dialisi: Normativa italiana, e proposta operative di controllo periodico. G Ital Nefrol. 1999; 7:165-170.
57. Ward RA. Contaminants in water used for hemodialysis. UpToDate Online. 2004; 12:3.
58. Surian M, Bonforte G, Scanziani R, et al. Trace elements and micropollutant anions in the dialysis and reinfusion fluid prepared on line for haemodiafiltration. Nephrol Dial Transplant. 1998; 13(Suppl 5):24-28.
59. Passlick-Deetjen J, Pohlmeier R. On-line hemodiafiltration. Gold standard or top therapy. Contrib Nephrol. 2002; 137:201-211.
60. Man NK. Controversies and isssues in hemodiafiltration therapy. Blood Purif. 2004; 22(Suppl 2):2-7.
61. Maduell F, Navarro V, Cruz MC, et al. Change from three times a week on-line hemodiafiltration to short daily on-line hemodiafiltration. Kidney Int. 2003; 23:344-349.